Get a Quote
Please use this form for bulk quantity requests or customized products.
Therapeutic Drug Monitoring
Research-use assays that quantify circulating levels of therapeutic drugs — infliximab, adalimumab, ustekinumab, vedolizumab and more — so you can relate drug exposure to response.
26Products
5 of 26 products
| Image | Product | Product Type | Application | Price | Status | ACTION |
|---|---|---|---|---|---|---|
|
Target: Infliximab | ELISA Kits, PK ELISA Kits | ELISA |
$1,226.00
Regular price
$1,226.00
|
In Stock at Manufacturer | |
|
Target: Infliximab | Antibodies, Primary Antibodies | ELISA |
From $452.00
Regular price
From $452.00
|
In Stock at Manufacturer | |
|
Target: Infliximab | ELISA Kits, ADA ELISA Kits | ELISA |
$1,498.00
Regular price
$1,498.00
|
In Stock at Manufacturer | |
|
Target: Infliximab | ELISA Kits | ELISA |
$520.00
Regular price
$520.00
|
In Stock at Manufacturer | |
|
Target: Infliximab | ELISA Kits | ELISA |
From $416.00
Regular price
From $416.00
|
In Stock at Manufacturer |
About Therapeutic Drug Monitoring
Therapeutic drug monitoring (TDM) reagents quantify the circulating concentration of a dosed drug — most often a biologic such as a TNF-α inhibitor — so researchers can relate exposure to response and keep levels inside the therapeutic window. This collection gathers research-use ELISA kits, biosimilar reference standards, and detection antibodies for measuring drug trough and free-drug levels of infliximab, adalimumab, ustekinumab, vedolizumab, and related therapeutics.
Choosing a drug-exposure assay: TDM vs Pharmacokinetics vs Immunogenicity
Three neighbouring assay families answer three different questions about a therapeutic. TDM is the format in this collection; the table shows when to reach for it versus its two siblings.
| Dimension | Therapeutic Drug Monitoring | Pharmacokinetics (PK) | Drug Immunogenicity (ADA/NAb) |
|---|---|---|---|
| What it measures | Concentration of the drug in a sample | Concentration of the drug over time | Antibodies the host raises against the drug |
| Analyte | Free / total drug | Free / total drug | Anti-drug antibody (ADA); neutralizing antibody (NAb) |
| Question answered | Is exposure inside the therapeutic window right now? | How is the drug absorbed, distributed, and cleared? | Is the host mounting an immune response that lowers exposure or efficacy? |
| Typical readout | Trough / free-drug level (µg/mL) | Cmax, AUC, t½, clearance | ADA titer; % neutralization |
| Usual stage | Dose management & exposure–response studies | Preclinical / early clinical characterization | Safety & loss-of-response investigation |
| Watch-outs | ADA in the sample can interfere with free-drug reading | Needs a time course, not a single point | Drug in the sample can mask ADA (drug tolerance) |
How to read this: TDM and PK both quantify the drug — the difference is intent. Use TDM when the goal is to check a level against a target window; use Pharmacokinetics when you need the full exposure profile over time. When exposure is unexpectedly low or a response fades, switch to Drug Immunogenicity to test for anti-drug antibodies — the three are complementary, and a complete study often runs all three on the same samples.
Recommended TDM kits
Human Infliximab ELISA Kit
View kit →Human Adalimumab ELISA Kit
View kit →Human Ustekinumab ELISA Kit
View kit →Infliximab (Remicade) Pharmacokinetic ELISA
View kit →Related reading
Trough-level monitoring of anti-TNF biologics
Free vs total drug assays: what the format changes
When loss of response means anti-drug antibodies